Literature DB >> 2917126

Chemosensitivity testing of fresh leukaemia cells using the MTT colorimetric assay.

P R Twentyman1, N E Fox, J K Rees.   

Abstract

We have determined the feasibility of using the MTT colorimetric assay for measuring the sensitivity of fresh leukaemia cells to cytotoxic agents. A linear relationship was seen between the number of leukaemic cells plated and the resulting absorbance in the MTT assay at day 4. For 2 X 10(5) cells/well from CLL peripheral lymphocytes, the mean absorbance (measured at 540 nm) was 0.41. Similar curves were obtained with the assay carried out between days 3 and 7. ID50 values for CLL lymphocytes exposed to adriamycin (ADM) were in the range of 0.02-0.29 micrograms/ml, a similar range to that given by the DiSC dye exclusion assay. Sensitization of leukaemia cells to ADM by verapamil or cyclosporin A could be demonstrated in some patients but not in others. The lymphocytes from one patient with prolymphocytic leukaemia were abnormally resistant to ionizing radiation. These cells also showed resistance to melphalan and adriamycin but not to vincristine. The MTT assay appears to offer an attractive option for in vitro chemosensitivity testing in leukaemia, determination of cross-resistance profiles and studies of resistance modifiers.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2917126     DOI: 10.1111/j.1365-2141.1989.tb06268.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  30 in total

1.  Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.

Authors:  Carlos M Galmarini; Galya Warren; Madapathage T Senanayake; Serguei V Vinogradov
Journal:  Int J Pharm       Date:  2010-05-24       Impact factor: 5.875

2.  P-glycoprotein-expressing tumor cells are resistant to anticancer drugs in human gastrointestinal cancer.

Authors:  T Hotta; H Tanimura; M Iwahashi; M Tani; T Tsunoda; K Noguchi; S Mizobata; K Arii; H Terasawa; M Nakamori; H Yamaue
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

3.  Chemotherapy in experimental brain tumor, part 1: in vitro colorimetric MTT assay.

Authors:  C M Hand; J R Vender; P Black
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

4.  Effects of febrile temperature on adenoviral infection and replication: implications for viral therapy of cancer.

Authors:  Stephen H Thorne; Gabriel Brooks; Yeun-Ling Lee; Tina Au; Lawrence F Eng; Tony Reid
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 5.  A review of the use of pteridophytes for treating human ailments.

Authors:  Xavier-Ravi Baskaran; Antony-Varuvel Geo Vigila; Shou-Zhou Zhang; Shi-Xiu Feng; Wen-Bo Liao
Journal:  J Zhejiang Univ Sci B       Date:  2018 Feb.       Impact factor: 3.066

6.  Test for chemotherapeutic sensitivity of cerebral gliomas: use of colorimetric MTT assay.

Authors:  J P Jordan; C M Hand; R S Markowitz; P Black
Journal:  J Neurooncol       Date:  1992-09       Impact factor: 4.130

7.  Methotrexate cytotoxicity determination using the MTT assay following enzymatic depletion of thymidine and hypoxanthine.

Authors:  M Haber; J Madafiglio; M D Norris
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

8.  Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines.

Authors:  Carlos M Galmarini; Galya Warren; Ekta Kohli; Arin Zeman; Anton Mitin; Serguei V Vinogradov
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

Review 9.  Prediction of response to drug therapy of cancer. A review of in vitro assays.

Authors:  W T Bellamy
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

10.  Synthesis and evaluation of L-glutamic Acid analogs as potential anticancer agents.

Authors:  C L Vishwanathan; S Deb; A Jain; T Lokhande; Aarti Juvekar
Journal:  Indian J Pharm Sci       Date:  2008 Mar-Apr       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.